Hyloris Pharmaceuticals SA (52U) Stock Price & Analysis

6 Followers

52U Stock Chart & Stats

€4.16-€0.32(22.71%)

At close: Nov 10 5:30 PM GMT+1

Day’s Range: EUR 4.16 - EUR 4.16
52-Week Range: EUR 3.39 - EUR 8.14
Previous Close: EUR 3.39
Volume: N/A
Average Volume (3M): 75
Market Cap: EUR 118.16M
Enterprise Value: EUR 119.47M
Total Cash (Recent Filing): EUR 24.15M
Total Debt (Recent Filing): EUR 1.81M
Price to Earnings (P/E): ―
Beta: 0.38
Next Earnings: Mar 17, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Hyloris Pharmaceuticals SA News

Hyloris Secures New China Licensing Pathway for Maxigesic IV

Hyloris Pharmaceuticals SA ( ($DE:52U) ) just unveiled an announcement. Hyloris Pharmaceuticals’ partner AFT Pharmaceuticals has signed an exclusive licensing deal with Chengdu Tongde Pharmaceuticals for the development, manufacture and

4M ago52U 0AB6

Hyloris Strikes Exclusive Orion Deal for Ready-to-Use Pantoprazole IV in Europe

Hyloris Pharmaceuticals SA ( ($DE:52U) ) just unveiled an update. Hyloris Pharmaceuticals has signed an exclusive license and supply agreement granting Finland’s Orion Corporation rights to register, market and commercialize

9M ago52U 0AB6

Hyloris Pharmaceuticals Reports Strong 2024 Results and Strategic Progress

Hyloris Pharmaceuticals SA ( ($DE:52U) ) just unveiled an announcement. Hyloris Pharmaceuticals reported a significant increase in revenue and a reduction in net losses for 2024, driven by growth in

1y ago52U 0AB6

Hyloris Pharmaceuticals Receives Positive IDMC Recommendation for Alenura Trial

Hyloris Pharmaceuticals SA ( ($DE:52U) ) has provided an update. Hyloris Pharmaceuticals has announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) to continue the Alenura clinical trial

1y ago52U 0AB6

Hyloris Pharmaceuticals Expands Pipeline with Ready-To-Use Pantoprazole IV

An announcement from Hyloris Pharmaceuticals SA ( ($DE:52U) ) is now available. Hyloris Pharmaceuticals has signed an exclusive licensing agreement to develop a ready-to-use intravenous formulation of pantoprazole, a drug

1y ago52U 0AB6

Hyloris Pharmaceuticals Reports Positive Study Results for Dofetilide IV

Hyloris Pharmaceuticals SA ( ($DE:52U) ) just unveiled an update. Hyloris Pharmaceuticals announced positive results from a pivotal study of Dofetilide IV, an innovative intravenous formulation for treating atrial fibrillation

1y ago52U 0AB6

Hyloris’ Valacyclovir Oral Suspension NDA Accepted by FDA

The latest update is out from Hyloris Pharmaceuticals SA ( ($DE:52U) ). Hyloris Pharmaceuticals announced that the FDA has accepted their New Drug Application for Valacyclovir oral suspension, setting a

1y ago52U 0AB6

Hyloris Partners with Colonis Pharma for UK Launch of Innovative Dental Product

Hyloris Pharmaceuticals SA ( ($DE:52U) ) has shared an announcement. Hyloris Pharmaceuticals has announced an exclusive licence and distribution agreement with Colonis Pharma for XTRAZA, a novel oral rinse designed

1y ago52U 0AB6

Hyloris Pharmaceuticals Updates on Subscription Rights and Voting Securities

An update from Hyloris Pharmaceuticals SA ( ($DE:52U) ) is now available. Hyloris Pharmaceuticals announced a change in its remaining subscription rights, impacting the total number of securities carrying voting

1y ago52U 0AB6

Hyloris Pharmaceuticals Issues New Warrants to Enhance Market Position

Hyloris Pharmaceuticals SA ( ($DE:52U) ) has provided an update. Hyloris Pharmaceuticals has announced the issuance of 650,000 new warrants under its ESOP Warrant plan 2025, following the expiry of

1y ago52U 0AB6

52U FAQ

What was Hyloris Pharmaceuticals SA’s price range in the past 12 months?

Hyloris Pharmaceuticals SA lowest stock price was €3.39 and its highest was €8.14 in the past 12 months.

What is Hyloris Pharmaceuticals SA’s market cap?

Hyloris Pharmaceuticals SA’s market cap is €118.16M.

When is Hyloris Pharmaceuticals SA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Hyloris Pharmaceuticals SA’s earnings last quarter?

Hyloris Pharmaceuticals SA released its earnings results on Sep 24, 2026. The company reported -€0.067 earnings per share for the quarter.

Is Hyloris Pharmaceuticals SA overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Hyloris Pharmaceuticals SA pay dividends?

Hyloris Pharmaceuticals SA does not currently pay dividends.

What is Hyloris Pharmaceuticals SA’s EPS estimate?

Hyloris Pharmaceuticals SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hyloris Pharmaceuticals SA have?

Hyloris Pharmaceuticals SA has 28,000,374 shares outstanding.

What happened to Hyloris Pharmaceuticals SA’s price movement after its last earnings report?

Hyloris Pharmaceuticals SA reported an EPS of -€0.067 in its last earnings report. Following the earnings report the stock price went up 5.57%.

Which hedge fund is a major shareholder of Hyloris Pharmaceuticals SA?

Currently, no hedge funds are holding shares in DE:52U

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and bringing to market pharmaceutical products designed to fulfill critical unmet medical needs. The company's focus areas include cardiovascular health, oncology, women's health, and other significant therapeutic domains. Its cardiovascular portfolio features treatments for conditions such as atrial fibrillation, acute coronary syndrome, advanced and congestive heart failure, and coronary heart disease. Beyond this, Hyloris addresses a diverse range of other ailments, including post-operative pain management, dental indications, severe and recurring vulvovaginal candidiasis, specific cancers (like acute myeloid leukemia and small cell lung cancer), interstitial cystitis/painful bladder syndrome (IC/PBS), attention deficit hyperactivity disorder (ADHD), and various viral infections. Established in 2012, Hyloris Pharmaceuticals SA is headquartered in Liège, Belgium.

Hyloris Pharmaceuticals SA (52U) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	11	5	6
Technical Analysis	3	5	2
Moving Averages	8	0	4

Technical Analysis >

Similar Stocks

Stocks similar to DE:52U
Company	Price & Change	Follow
DE:9YGDeep Value Driller AS

Compare DE:52U Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

52U Stock Chart & Stats

Hyloris Pharmaceuticals SA News

Hyloris Secures New China Licensing Pathway for Maxigesic IV

Hyloris Strikes Exclusive Orion Deal for Ready-to-Use Pantoprazole IV in Europe

Hyloris Pharmaceuticals Reports Strong 2024 Results and Strategic Progress

Hyloris Pharmaceuticals Receives Positive IDMC Recommendation for Alenura Trial

Hyloris Pharmaceuticals Expands Pipeline with Ready-To-Use Pantoprazole IV

Hyloris Pharmaceuticals Reports Positive Study Results for Dofetilide IV

Hyloris’ Valacyclovir Oral Suspension NDA Accepted by FDA

Hyloris Partners with Colonis Pharma for UK Launch of Innovative Dental Product

Hyloris Pharmaceuticals Updates on Subscription Rights and Voting Securities

Hyloris Pharmaceuticals Issues New Warrants to Enhance Market Position

52U FAQ

Company Description

Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA (52U) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium